Advocacy Partner:
American Partnership For Eosinophilic Disorders (APFED)
About the American Partnership For Eosinophilic Disorders (APFED)
The American Partnership for Eosinophilic Disorders (APFED) is a 501c3 nonprofit organization founded in December 2001 by a group of mothers of young children living with eosinophil-associated diseases. We are a patient advocacy group dedicated to improving the lives of those living with eosinophilic disorders.
Contact: Mary Jo Strobel – Executive Director
Phone: (713) 493-7749 Ext. 2
Email: [email protected]
Resources
EoS Support Webinar Series
APFED’s EoS Support Webinar Series offers a virtual forum for patients and families to connect and learn. Join various experts for hour-long webinars on a variety of topics, such as diagnostics, treatments, and daily living with eosinophil-associated diseases, including eosinophilic granulomatosis with polyangiitis (EGPA).
Publishing Schedule: Monthly
Registration Link
EGPA Clinical Trial Data Recording: The 2025 Annual Patient Conference
APFED’s annual patient conference offers an engaging opportunity to connect with experts, hear the latest research updates, and learn practical strategies for living with eosinophil-associated diseases, including EGPA. This year’s program included findings from a recent clinical trial on eosinophilic granulomatosis with polyangiitis (EGPA)—visit apfed.org/conference to register at no cost to access the recordings.
Registration Link
APFED Connect Virtual Support Groups
APFED offers virtual support groups designed to help patients and caregivers connect, share experiences, and find community. This includes groups specifically for individuals living with rare subsets such as EGPA, HES, and EF.
Explore all available support groups and find the one that best fits your needs: https://apfed.org/
Upcoming events
About Advocacy Partners
The information above is provided by our partner. Learn more about our advocacy partners here.
Recent Posts
- Preparing for hip replacement surgery with ANCA vasculitis
- Protein building block may be a therapeutic target for childhood AAV
- European agency reevaluates AAV drug Tavneos after trial data concerns
- Living with chronic illness has taught me to hold on loosely
- Rituximab matches cyclophosphamide in inducing AAV remission: Review
